---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024818"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-11-24T23:59:59+00:00"
generated_at: "2026-05-16T17:23:10.887282+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharma reports Telomir-1 reduces PSA in prostate cancer cells in dose-related manner

## Summary
- Telomir-1 reduced PSA levels in dose-related manner in androgen-responsive human prostate cancer cells (LNCaP) in vitro.
- Also associated with reductions in cellular energy metabolism and viability in the same study.
- In prior PC3 xenograft mouse model, Telomir-1 reduced tumor volume as single agent; full reduction with paclitaxel combo without mortality.
- Paclitaxel alone achieved full tumor reduction but had high mortality; Telomir-1 combo showed no treatment-related deaths.
- Company advancing IND-enabling activities for planned IND submission across oncology and aging-related conditions.

## SEC filing metadata
- accession: 0001493152-25-024818
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-11-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225024818/0001493152-25-024818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225024818/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024818
- JSON: https://secwatch.observer/filing/0001493152-25-024818.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024818.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.